Acceleron is developing its lead product candidate, luspatercept, in a strategic global partnership with Celgene Corporation, the industry leader in hematology.
Discovered by Acceleron, luspatercept is a first-in-class erythroid (red blood cell) maturation agent being developed to treat patients suffering from anemia due to myelodysplastic syndromes (MDS), beta-thalassemia and myelofibrosis. These serious blood disorders are marked by a late-stage defect in the maturation of red blood cells, and this defect results in chronic anemia that can affect quality of life and negatively impact a patient’s physical, social, and emotional well-being.
In late 2018, Acceleron and Celgene presented results of Phase 3 clinical trials of luspatercept treatment in patients with MDS- and beta-thalassemia-associated anemia. In April 2019, the companies submitted applications to the U.S. FDA and the European Medicines Agency for approval of luspatercept for the treatment of patients with lower-risk MDS- or beta-thalassemia-associated anemia requiring red blood cell transfusions.
Luspatercept is also being evaluated in a Phase 3 trial in treatment-naïve MDS patients, a phase 2 trial in non-transfusion-dependent beta-thalassemia, and a Phase 2 trial in myelofibrosis.
Acceleron is also collaborating with Adimab, an innovator in antibody discovery and optimization. Adimab is working to identify fully human antibodies that Acceleron may develop and commercialize. We are funding the research and have the option to exclusively license newly discovered antibodies.
Acceleron is dedicated to the discovery and development of innovative, life-changing medicines for patients with a wide range of serious and rare diseases. Our research focuses on harnessing the power of the TGF-beta protein superfamily, the target-rich area of biology behind the body’s remarkable capacity for cellular growth and repair.
We would welcome discussions on meaningful strategic collaborations. You can reach us at BD@acceleronpharma.com.